GlassScriptPhysician profile
John R Gavini
NPI 1750328803
$10,660.83
in general payments reported to CMS, 2019-2025
48 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $1,466 · 2021: $2,152 · 2022: $1,337 · 2023: $1,221 · 2024: $1,363 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,015.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,172.22 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Novo Nordisk INC | $825.16 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $754.29 | 2020-2024 | |
| Amgen INC. | $626.78 | 2019-2025 | Otezla, Repatha, Evenity |
| Mylan Specialty L.P. | $501.81 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $466.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $381.09 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $317.96 | 2019-2024 | Linzess |
| Ardelyx, INC. | $271.96 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $264.23 | 2019-2024 | Verquvo |
| Astellas Pharma US INC | $236.42 | 2019-2024 | Veozah |
| Pfizer INC. | $223.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $222.91 | 2019-2022 | |
| Glaxosmithkline, LLC. | $222.87 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gavini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.